ANN ARBOR, Mich., Oct. 12 /PRNewswire/ -- Adeona Pharmaceuticals, Inc., (Amex: AEN) announced five scientific publications on the role of copper toxicity and zinc deficiency in Alzheimer's disease and cognitive decline. The author of all these publications is Adeona's scientific founder and consultant, George J. Brewer, M.D., the Morton S. and Henrietta Sellner Emeritus Professor of Human Genetics and Internal Medicine at the University of Michigan.
The first two publications describe the results of Adeona's observational clinical study of zinc and copper status in 29 patients with Alzheimer's disease, 30 patients with Parkinson's disease, and 29 age- and sex-matched controls (CopperProof-1). The CopperProof-1 study was conducted at Albany Medical Center by Earl Zimmerman, M.D., Director of the Alzheimer's Centers, Eric Molho, M.D., Director of the Parkinson's Disease Centers and Dzintra Celmins, M.D., of the Parkinson's Disease Centers.
The first publication entitled, "Subclinical Zinc Deficiency in Alzheimer's Disease and Parkinson's Disease," was published in the November 2010 issue of the American Journal of Alzheimer's Disease & Other Dementias. Serum zinc and urinary zinc were compared across the three groups of patients. The results showed a significantly lower serum zinc level in patients with Alzheimer's and patients with Parkinson's than in controls.
The second publication entitled, "Copper and Ceruloplasmin Abnormalities in Alzheimer's Disease," was published in the September 2010 issue of the American Journal of Alzheimer's Disease and Other Dementias. That publication describes how copper may play a role in the pathogenesis of Alzheimer's disease and increased exposure to environmental copper and/or defective ceruloplasmin function could directly be contributing to the Alzheimer's epidemic.
Since the initial presenta